Xbrane Biopharma

Xbrane Biopharma AB’s (publ.) (”Xbrane”) interim report for January - June 2022 is now available on the Company’s website, www.xbrane.com.

Financial overview second quarter 2022

• Revenue amounted to SEK 15.6 m (2.5).
• Other operating income was SEK 11.4 m (0.4).
• EBITDA amounted to SEK -28.4 m (-53.8).
• R&D costs amounted to SEK -52.9 m (-49.9) corresponding to 89% (84) of total operating costs.
• The net result for the period was SEK -33.8 m (-59.2).
• Earnings per share amounted to SEK -1.35 (-2.67).
• Cash and cash equivalents at the end of the period amounted to SEK 250.1 m (129.3).

Financial overview first half of 2022

• Revenue amounted to SEK 22.8 m (5.1).
• Other operating income was SEK 17.6 m (2.5).
• EBITDA amounted to SEK -61.3 m (-100.6).
• R&D costs amounted to SEK -88.9 m (-95.3) corresponding to 81% (84) of total operating costs.
• The net result for the period was SEK -69.9 m (-110.4).
• Earnings per share amounted to SEK -2.79 (-4.97).
• Cash and cash equivalents at the end of the period amounted to SEK 250.1 m (129.3).

Figures in parentheses refer to the corresponding period last year.

Significant events in the second quarter 2022

• In May, it was announced that the company had withdrawn its marketing authorization application for its LUCENTIS® biosimilar candidate following a request for additional information from the FDA (US equivalent to the Swedish Medicines Agency).
• At the end of June, a change in the number of shares and voting rights in Xbrane linked to a long-term share saving program, was announced.

Significant events after the end of the quarter

• In early July, an update was provided regarding supplements and recommendations received from the FDA. The application is planned to be resubmitted during 2022.

*) Production is initiated after the expiration of relevant patents

Xbrane Biopharma AB invites to a teleconference for investors, analysts and media on July the 22nd, 2022, at 10.00 a.m. CET. See the link to the presentation below.

Web link:
Presentation of interim Report January – June 2022